SB-061

Overview: 

SB-061 is a biomimetic proteoglycan that protects against osteoarthritis and promotes tissue/joint repair.  SB-061 is delivered directly to the joint, like a steroid injection or viscosupplement, where it binds and protects the remaining cartilage from further degradation while also providing mechanical support.  

Status: 

Purdue Faculty: 

Dr. Alyssa Panitch formerly of Purdue, now of UC Davis

Clinical Trial Information: 

Phase 2 Trial - A Trial of SB-061 in Osteoarthritis of the Knee

Phase 2 Trial - A Trial of a Single Delivery of SB-061 in Osteoarthritis of the Knee (MODIFY2)

Development Parnter: 

Symic Biomedical

Research Articles: 

A phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in patients with symptomatic knee osteoarthritis

Biomimetic Molecules Lower Catabolic Expression and Prevent Chondroitin Sulfate Degradation in an Osteoarthritic ex Vivo Model

Preservation of the Structure of Enzymatically-Degraded Bovine Vitreous Using Synthetic Proteoglycan Mimics

Biomimetic Aggrecan Reduces Cartilage Extracellular Matrix From Degradation and Lowers Catabolic Activity in Ex Vivo and In Vivo Models